KEMSTRO Drug Patent Profile

✉ Email this page to a colleague

When do Kemstro patents expire, and when can generic versions of Kemstro launch?

Kemstro is a drug marketed by Ucb Inc and is included in one NDA.

The generic ingredient in KEMSTRO is baclofen. There are twenty-one drug master file entries for this compound. Sixty-five suppliers are listed for this compound. Additional details are available on the baclofen profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Kemstro

A generic version of KEMSTRO was approved as baclofen by IVAX SUB TEVA PHARMS on July 21^st, 1988.

Sign Up

AI Research Assistant

Questions you can ask:

What is the 5 year forecast for KEMSTRO?
What are the global sales for KEMSTRO?
What is Average Wholesale Price for KEMSTRO?

Summary for KEMSTRO

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	150
Clinical Trials:	3
Patent Applications:	3,916
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for KEMSTRO
DailyMed Link:	KEMSTRO at DailyMed

Drug patent expirations by year for KEMSTRO

Recent Clinical Trials for KEMSTRO

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Pennsylvania Department of Health	Phase 2
University of Pennsylvania	Phase 2
National Institutes of Health (NIH)	Phase 2

See all KEMSTRO clinical trials

US Patents and Regulatory Information for KEMSTRO

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ucb Inc	KEMSTRO	baclofen	TABLET, ORALLY DISINTEGRATING;ORAL	021589-001	Oct 30, 2003		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Ucb Inc	KEMSTRO	baclofen	TABLET, ORALLY DISINTEGRATING;ORAL	021589-002	Oct 30, 2003		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for KEMSTRO

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Ucb Inc	KEMSTRO	baclofen	TABLET, ORALLY DISINTEGRATING;ORAL	021589-001	Oct 30, 2003	⤷ Sign Up	⤷ Sign Up
Ucb Inc	KEMSTRO	baclofen	TABLET, ORALLY DISINTEGRATING;ORAL	021589-002	Oct 30, 2003	⤷ Sign Up	⤷ Sign Up
Ucb Inc	KEMSTRO	baclofen	TABLET, ORALLY DISINTEGRATING;ORAL	021589-002	Oct 30, 2003	⤷ Sign Up	⤷ Sign Up
Ucb Inc	KEMSTRO	baclofen	TABLET, ORALLY DISINTEGRATING;ORAL	021589-001	Oct 30, 2003	⤷ Sign Up	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

International Patents for KEMSTRO

See the table below for patents covering KEMSTRO around the world.

Subscribe to access the full database, or Sign Up
Country	Patent Number	Title	Estimated Expiration
European Patent Office	2147669	Formule de dosage robuste à dissolution rapide (Rapidly dissolving robust dosage form)	⤷ Sign Up
Denmark	2266538		⤷ Sign Up
Australia	726336		⤷ Sign Up
Japan	2012162558	RAPIDLY DISSOLVING ROBUST DOSAGE FORM	⤷ Sign Up
>Country	>Patent Number	>Title	>Estimated Expiration

AI Research Assistant

Questions you can ask:

Summary for KEMSTRO

Recent Clinical Trials for KEMSTRO

Make Better Decisions: Try a trial or see plans & pricing